Forside  
Velg data du ønsker med i utskriften
Tittel Engelsk tittel Versjon Status
IS-nr
Revisjonsdato Publiseringsdato
Utgiver(e) Redaktør Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av blære- og urotelkreft
  • Engelsk tittel - Bladder cancer
  • Versjon - 3
  • Status - Under utarbeidelse
  • IS-nr - 2778
  • ISBN -
  • DOI -
  • Revisjonsdato - 14.11.2018
  • Neste revisjon -
  • Publikasjonsdato - 08.04.2013
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør - Erik Skaaheim Haug, Urolog, Sykehuset i Vestfold HF, HSØ
  • Publikasjonstype - Nasjonale retningslinjer
Vedlegg
 
  1. Larsen IK, red. Cancer in Norway 2015. Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2016. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2015/cin2015-special_issue-web.pdf 
  2. Andreassen BK, Aagnes B, Gislefoss R, Andreassen M, Wahlqvist R. Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981–2014. BMC Cancer 2016;16(1):799.
  3. Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999;161(5):1494–7.
  4. Rink M, Crivelli JJ, Shariat SF, Chun FK, Messing EM, Soloway MS. Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. Eur Urol Focus 2015;1(1):17–27.
  5. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306(7):737–45.
  6. Parkin DM, Boyd L, Walker LC. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer 2011;105(Suppl 2):S77–81.
  7. Brown T, Slack R, Rushton L. Occupational cancer in Britain. Urinary tract cancers: bladder and kidney. Br J Cancer 2012;107(Suppl 1):S76–84.
  8. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002;10(6):311–22.
  9. Grotenhuis AJ, Vermeulen SH, Kiemeney LA. Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response. Future Oncol 2010;6(9):1433–60.
  10. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366(9486):649–59.
  11. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010;42(11):978–84.
  12. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010;42(5):415–9.
  13. Barrow PJ, Ingham S, O’Hara C, Green K, McIntyre I, Lalloo F, et al. The spectrum of urological malignancy in Lynch syndrome. Fam Cancer 2013;12(1):57–63.
  14. van der Post RS, Kiemeney LA, Ligtenberg MJ, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010;47(7):464–70.
  15. Vasen HF, Möslein G, Alonso A, Bernstein I, Bertario L, Blanco I, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007;44(6):353–62.
  16. Bernstein IT, Myrhøj T. Surveillance for urinary tract cancer in Lynch syndrome. Fam Cancer 2013;12(2):279–84.
  17. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68(5):868–79.
  18. Mork M, Hubosky SG, Rouprêt M, Margulis V, Raman J, Lotan Y, et al. Lynch Syndrome: A Primer for Urologists and Panel Recommendations. J Urol 2015;194(1):21–9.
  19. Metcalfe MJ, Petros FG, Rao P, Mork ME, Xiao L, Broaddus RR, et al. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol 2018;199(1):60–5.
  20. Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 2016;352:i851.
  21. Bartkowiak D, Humble N, Suhr P, Hagg J, Mair K, Polivka B, et al. Second cancer after radiotherapy, 1981–2007. Radiother Oncol 2012;105(1):122–6.
  22. Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 2009;91(1):4–15; discussion 1–3.
  23. Colt J, Friesen M, Stewart P, Donguk P, Johnson A, Schwenn M, et al. 0084 A Case-Control Study of Occupational Exposure to Metalworking Fluids and Bladder Cancer Risk among Men. Occup Environ Med 2014;71(Suppl 1):A71.
  24. Rota M, Bosetti C, Boccia S, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: an updated systematic review and a meta-analysis to 2014. Arch Toxicol 2014;88(8):1479–90.
  25. Sosnowski R, Przewozniak K. The role of the urologist in smoking cessation: Why is it important? Urol Oncol 2014;33(1):30–9.
  26. Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol 2011;60(4):713–20.
  27. Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 2013;63(4):724–32.
  28. Serretta V, Altieri V, Morgia G, Di Lallo A, Carrieri G, Allegro R. Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. Urology 2013;81(2):277–81.
  29. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014;65(4):742–54.
  30. Lamm DL, Riggs DR. Enhanced immunocompetence by garlic: role in bladder cancer and other malignancies. J Nutr 2001;131(3s):1067s-70s.
  31. Catsburg CE, Gago-Dominguez M, Yuan JM, Castelao JE, Cortessis VK, Pike MC, et al. Dietary sources of N-nitroso compounds and bladder cancer risk: findings from the Los Angeles bladder cancer study. Int J Cancer 2014;134(1):125–35.
  32. Bricker GV, Riedl KM, Ralston RA, Tober KL, Oberyszyn TM, Schwartz SJ. Isothiocyanate metabolism, distribution, and interconversion in mice following consumption of thermally processed broccoli sprouts or purified sulforaphane. Mol Nutr Food Res 2014;58(10):1991–2000.
  33. Wennersten C, Andersson G, Boman K, Nodin B, Gaber A, Jirstrom K. Incident urothelial cancer in the Malmo Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagn Pathol 2014;9(1):189.
  34. Andersson G, Wennersten C, Gaber A, Boman K, Nodin B, Uhlen M, et al. Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC Urol 2014;14:36.
  35. Bhattacharya A, Li Y, Shi Y, Zhang Y. Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. Carcinogenesis 2013;34(11):2593–9.
  36. Stenzl A, Witjes JA, Cowan NC, De Santis M, Kuczyk M, Lebret T, et al. Guidelines on bladder cancer, muscle-invasive and metastatic. Arnhem: European Association of Urology; 2011. Tilgjengelig fra: http://www.uroweb.org/gls/pdf/07_%20Bladder%20Cancer.pdf 
  37. Urinary Bladder. I: Sobin DH, Gospodarwicz MK, Wittekind C, red. TNM Classification of Malignant Tumours. 7. utg. Oxford: Wiley-Blackwell; 2010. s. 262–5.
  38. Pakkerforløp for blærekreft. rev. utg. Oslo: Helsedirektoratet; 2016. IS-2520. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/pakkeforlop-for-blerekreft 
  39. Mohr DN, Offord KP, Melton LJ, 3rd. Isolated asymptomatic microhematuria: a cross-sectional analysis of test-positive and test-negative patients. J Gen Intern Med 1987;2(5):318–24.
  40. Loo RK, Lieberman SF, Slezak JM, Landa HM, Mariani AJ, Nicolaisen G, et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc 2013;88(2):129–38.
  41. Malmström PU. Time to abandon testing for microscopic haematuria in adults? BMJ 2003;326(7393):813–5.
  42. Elmussareh M, Young M, Ordell Sundelin M, Bak-Ipsen CB, Graumann O, Jensen JB. Outcomes of haematuria referrals: two-year data from a single large university hospital in Denmark. Scand J Urol 2017;51(4):282–9.
  43. Ordell Sundelin M, Jensen JB. Asymptomatic microscopic hematuria as a predictor of neoplasia in the urinary tract. Scand J Urol 2017;51(5):373–5.
  44. van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, et al. Post-contrast acute kidney injury – Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2018;28(7):2845–55.
  45. van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2018;28(7):2856–69.
  46. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41(3):284–9.
  47. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003;169(6):1975–82.
  48. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, 3rd, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66(6 Suppl 1):35–63.
  49. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61(1):109–18; discussion 18.
  50. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47(6):736–48.
  51. Hakenberg OW, Compérat E, Minhas S, Necchi A, Protzel C, Watkin N, et al. EAU Guidelines on Penile Cancer. Arnhem: European Association of Urology; 2017. Tilgjengelig fra: http://uroweb.org/wp-content/uploads/12-Penile-Cancer_2017_web.pdf 
  52. Ericson KM, Isinger AP, Isfoss BL, Nilbert MC. Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma. BMC Cancer 2005;5:23.
  53. Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012;30(35):4409–15.
  54. Cheng L. Renal pelvis and ureter. I: Bostwick DG, Cheng L, red. Urologic surgical pathology. 2. utg. St. Louis, Mo: Mosby Elsevier; 2008. s. 174.
  55. Brierley JD, Gospodarowicz M, Wittekind C, red. TNM Classification of Malignant Tumours. 8. utg. New York: Wiley-Blackwell; 2017.
  56. Inman BA, Tran VT, Fradet Y, Lacombe L. Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer 2009;115(13):2853–62.
  57. Raman JD, Shariat SF, Karakiewicz PI, Lotan Y, Sagalowsky AI, Roscigno M, et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol 2011;29(6):716–23.
  58. Ito Y, Kikuchi E, Tanaka N, Miyajima A, Mikami S, Jinzaki M, et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol 2011;185(5):1621–6.
  59. Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 2010;76(4):895–901.
  60. Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 2010;184(1):69–73.
  61. Yamany T, van Batavia J, Ahn J, Shapiro E, Gupta M. Ureterorenoscopy for upper tract urothelial carcinoma: how often are we missing lesions? Urology 2015;85(2):311–5.
  62. Rojas CP, Castle SM, Llanos CA, Santos Cortes JA, Bird V, Rodriguez S, et al. Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urol Oncol 2013;31(8):1696–700.
  63. Chitale S, Mbakada R, Irving S, Burgess N. Nephroureterectomy for transitional cell carcinoma – the value of pre-operative histology. Ann R Coll Surg Engl 2008;90(1):45–50.
  64. Fossa SD, Ous S, Berner A. Clinical significance of the «palpable mass» in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. Br J Urol 1991;67(1):54–60.
  65. Wijkstrom H, Norming U, Lagerkvist M, Nilsson B, Naslund I, Wiklund P. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. Br J Urol 1998;81(5):686–91.
  66. Kramer MW, Altieri V, Hurle R, Lusuardi L, Merseburger AS, Rassweiler J, et al. Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. Eur Urol Focus 2017;3(6):567–76.
  67. Hurle R, Lazzeri M, Colombo P, Buffi N, Morenghi E, Peschechera R, et al. «En Bloc» Resection of Nonmuscle Invasive Bladder Cancer: A Prospective Single-center Study. Urology 2016;90:126–30.
  68. Picozzi SC, Ricci C, Gaeta M, Casellato S, Bozzini G, Ratti D, et al. Is it oncologically safe performing simultaneous transurethral resection of the bladder and prostate? A meta-analysis on 1,234 patients. Int Urol Nephrol 2012;44(5):1325–33.
  69. Tsivian A, Shtricker A, Sidi AA. Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver? J Urol 2003;170(6 Pt 1):2241–3.
  70. Matzkin H, Soloway MS, Hardeman S. Transitional cell carcinoma of the prostate. J Urol 1991;146(5):1207–12.
  71. Mungan MU, Canda AE, Tuzel E, Yorukoglu K, Kirkali Z. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol 2005;48(5):760–3.
  72. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft i tykktarm og endetarm. Oslo: Helsedirektoratet; 2017. IS-2644. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-kreft-i-tykktarm-og-endetarm 
  73. Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007;178(4 Pt 1):1201–5; discussion 5.
  74. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41(5):523–31.
  75. Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003;43(3):241–5.
  76. Jahnson S, Wiklund F, Duchek M, Mestad O, Rintala E, Hellsten S, et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol 2005;39(3):206–10.
  77. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165(3):808–10.
  78. Jakse G, Algaba F, Malmström PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004;45(5):539–46; discussion 46.
  79. Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, et al. Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007;69(2):260–4.
  80. Jichlinski P, Guillou L, Karlsen SJ, Malmström PU, Jocham D, Brennhovd B, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. J Urol 2003;170(1):226–9.
  81. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171(1):135–8.
  82. Mowatt G, N’Dow J, Vale L, Nabi G, Boachie C, Cook JA, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care 2011;27(1):3–10.
  83. Draga RO, Grimbergen MC, Kok ET, Jonges TN, van Swol CF, Bosch JL. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy. Eur Urol 2010;57(4):655–60.
  84. Ray ER, Chatterton K, Khan MS, Chandra A, Thomas K, Dasgupta P, et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int 2010;105(6):789–94.
  85. Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 2011;108(8 Pt 2):E297–303.
  86. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184(5):1907–13.
  87. Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int 2012;110(11 Pt B):E680–7.
  88. Drejer D, Béji S, Munk Nielsen A, Høyer S, Wrist Lam G, Jensen JB. Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study. Scand J Urol 2017;51(2):120–3.
  89. Ye Z, Hu J, Song X, Li F, Zhao X, Chen S, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. Sci Rep 2015;5:10905.
  90. Naito S, Algaba F, Babjuk M, Bryan RT, Sun YH, Valiquette L, et al. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results. Eur Urol 2016;70(3):506–15.
  91. Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149(4):749–52.
  92. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995;153(3 Pt 2):934–41.
  93. Solsona E, Iborra I, Ricós JV, Monrós JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999;161(4):1120–3.
  94. Gudjónsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009;55(4):773–80.
  95. Onishi T, Sasaki T, Hoshina A, Yabana T. Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. Anticancer Res 2011;31(4):1471–4.
  96. Onishi T, Sugino Y, Shibahara T, Masui S, Yabana T, Sasaki T. Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. BJU Int 2017;119(2):276–82.
  97. Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol 2016;69(2):231–44.
  98. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63(4):682–6.
  99. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168(5):1964–70.
  100. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):90–5.
  101. Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67(6):1216–23.
  102. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88(3):209–16.
  103. Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93(4):485–90.
  104. Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63(3):462–72.
  105. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44(4):429–34.
  106. Martinez-Pineiro JA, Flores N, Isorna S, Solsona E, Sebastian JL, Pertusa C, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89(7):671–80.
  107. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Gomez JM, Martin MG, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174(4 Pt 1):1242–7.
  108. Jakse G, Hall R, Bono A, Holtl W, Carpentier P, Spaander JP, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 2001;40(2):144–50.
  109. Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66(6 Suppl 1):90–107.
  110. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 2000;163(1):68–71.
  111. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163(4):1124–9.
  112. de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). J Urol 2005;173(2):405–9.
  113. Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002;167(6):2408–12.
  114. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19(3):499–508.
  115. Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol 2008;15(4):309–13.
  116. Palou J, Baniel J, Klotz L, Wood D, Cookson M, Lerner S, et al. Urothelial carcinoma of the prostate. Urology 2007;69(1 Suppl):50–61.
  117. Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. Eur Urol 2004;45(6):730–5.
  118. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57(1):60–70.
  119. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003;169(5):1706–8.
  120. Herr HW, Scher HI. Surgery of invasive bladder cancer: is pathologic staging necessary? Semin Oncol 1990;17(5):590–7.
  121. Sternberg CN, Pansadoro V, Calabro F, Schnetzer S, Giannarelli D, Emiliozzi P, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 2003;97(7):1644–52.
  122. Figueroa AJ, Stein JP, Dickinson M, Skinner EC, Thangathurai D, Mikhail MS, et al. Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer 1998;83(1):141–7.
  123. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA, Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 2003;170(4 Pt 1):1085–7.
  124. Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003;169(1):110–5.
  125. Huncharek M, Muscat J, Geschwind JF. Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res 1998;18(3B):1931–4.
  126. Widmark A, Flodgren P, Damber JE, Hellsten S, Cavallin-Stahl E. A systematic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol 2003;42(5–6):567–81.
  127. Stenzl A, Nagele U, Kuczyk M, Sievert K-D, Anastasiadis A, Seibold J, et al. Cystectomy – Technical Considerations in Male and Female Patients. EAU Update Series 2005;3(3):138–46.
  128. Stenzl A, Bartsch G, Rogatsch H. The remnant urothelium after reconstructive bladder surgery. Eur Urol 2002;41(2):124–31.
  129. Hernandez V, Linares E, Dunn J, Yuan Y, MacLennan S, Lam T, et al. What are the oncological and functional outcomes of sexual-function preserving cystectomy compared with standard radical cystectomy in men with bladder cancer? [Protokoll]. PROSPERO 2015;CRD42015020742. Tilgjengelig fra: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015020742.
  130. Veskimae E, Neuzillet Y, Rouanne M, MacLennan S, Lam TBL, Yuan Y, et al. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU Int 2017;120(1):12–24.
  131. Furrer MA, Studer UE, Gross T, Burkhard FC, Thalmann GN, Nguyen DP. Nerve-sparing radical cystectomy has a beneficial impact on urinary continence after orthotopic bladder substitution, which becomes even more apparent over time. BJU Int 2018;121(6):935–44.
  132. Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 2005;23(10):2358–65.
  133. Ghoneim MA, Abol-Enein H. Lymphadenectomy with cystectomy: is it necessary and what is its extent? Eur Urol 2004;46(4):457–61.
  134. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002;167(3):1295–8.
  135. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000;85(7):817–23.
  136. Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 1998;160(6 Pt 1):2015–9.
  137. Studer UE, Collette L. Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy. Eur Urol 2006;50(5):887–9.
  138. Roth B, Wissmeyer MP, Zehnder P, Birkhauser FD, Thalmann GN, Krause TM, et al. A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur Urol 2010;57(2):205–11.
  139. Bruins HM, Veskimae E, Hernandez V, Imamura M, Neuberger MM, Dahm P, et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol 2014;66(6):1065–77.
  140. Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 2011;186(4):1261–8.
  141. Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009;55(1):164–74.
  142. Cookson MS, Chang SS, Wells N, Parekh DJ, Smith JA, Jr. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol 2003;169(1):101–4.
  143. Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol 2010;184(3):990–4; quiz 1235.
  144. Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012;61(5):1039–47.
  145. Porter MP, Gore JL, Wright JL. Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. World J Urol 2011;29(1):73–7.
  146. Wilson TG, Guru K, Rosen RC, Wiklund P, Annerstedt M, Bochner BH, et al. Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. Eur Urol 2015;67(3):363–75.
  147. Haber GP, Campbell SC, Colombo JR, Jr., Fergany AF, Aron M, Kaouk J, et al. Perioperative outcomes with laparoscopic radical cystectomy: «pure laparoscopic» and «open-assisted laparoscopic» approaches. Urology 2007;70(5):910–5.
  148. Novara G, Catto JW, Wilson T, Annerstedt M, Chan K, Murphy DG, et al. Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur Urol 2015;67(3):376–401.
  149. Yuh B, Wilson T, Bochner B, Chan K, Palou J, Stenzl A, et al. Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. Eur Urol 2015;67(3):402–22.
  150. Fahmy O, Asri K, Schwentner C, Stenzl A, Gakis G. Current status of robotic assisted radical cystectomy with intracorporeal ileal neobladder for bladder cancer. J Surg Oncol 2015;112(4):427–9.
  151. Tan WS, Khetrapal P, Tan WP, Rodney S, Chau M, Kelly JD. Robotic Assisted Radical Cystectomy with Extracorporeal Urinary Diversion Does Not Show a Benefit over Open Radical Cystectomy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. PloS One 2016;11(11):e0166221.
  152. Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Paz GE, Donat SM, et al. Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol 2015;67(6):1042–50.
  153. Son SK, Lee NR, Kang SH, Lee SH. Safety and Effectiveness of Robot-Assisted Versus Open Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis. J Laparoendosc Adv Surg Tech A 2017;27(11):1109–20.
  154. Nguyen DP, Al Hussein Al Awamlh B, Wu X, O’Malley P, Inoyatov IM, Ayangbesan A, et al. Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer. Eur Urol 2015;68(3):399–405.
  155. Tanrikut C, McDougal WS. Acid-base and electrolyte disorders after urinary diversion. World J Urol 2004;22(3):168–71.
  156. Farnham SB, Cookson MS. Surgical complications of urinary diversion. World J Urol 2004;22(3):157–67.
  157. Madersbacher S, Schmidt J, Eberle JM, Thoeny HC, Burkhard F, Hochreiter W, et al. Long-term outcome of ileal conduit diversion. J Urol 2003;169(3):985–90.
  158. Neal DE. Complications of ileal conduit diversion in adults with cancer followed up for at least five years. Br Med J (Clin Res Ed) 1985;290(6483):1695–7.
  159. Wood DN, Allen SE, Hussain M, Greenwell TJ, Shah PJ. Stomal complications of ileal conduits are significantly higher when formed in women with intractable urinary incontinence. J Urol 2004;172(6 Pt 1):2300–3.
  160. Wiesner C, Stein R, Pahernik S, Hahn K, Melchior SW, Thuroff JW. Long-term followup of the intussuscepted ileal nipple and the in situ, submucosally embedded appendix as continence mechanisms of continent urinary diversion with the cutaneous ileocecal pouch (Mainz pouch I). J Urol 2006;176(1):155–9.
  161. Wiesner C, Bonfig R, Stein R, Gerharz EW, Pahernik S, Riedmiller H, et al. Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs. World J Urol 2006;24(3):315–8.
  162. Hautmann RE, Volkmer BG, Schumacher MC, Gschwend JE, Studer UE. Long-term results of standard procedures in urology: the ileal neobladder. World J Urol 2006;24(3):305–14.
  163. Thoeny HC, Sonnenschein MJ, Madersbacher S, Vock P, Studer UE. Is ileal orthotopic bladder substitution with an afferent tubular segment detrimental to the upper urinary tract in the long term? J Urol 2002;168(5):2030–4.
  164. Stein JP, Clark P, Miranda G, Cai J, Groshen S, Skinner DG. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 2005;173(4):1163–8.
  165. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rodel CM, et al. Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol 2014;66(1):120–37.
  166. Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kubler H, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol 2018;36(2):43–53.
  167. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366(16):1477–88.
  168. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61(4):705–11.
  169. Mirza A, Choudhury A. Bladder Preservation for Muscle Invasive Bladder Cancer. Bladder Cancer 2016;2(2):151–63.
  170. Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170(5):1772–6.
  171. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 2013;63(1):58–66.
  172. Dahl O, Lehne G, Baksaas I, Kvaløy S, Christoffersen T, red. Medikamentell kreftbehandling, Cytosta­tikaboken. 7. utg. Oslo: Farmakologisk institutt, Det medisinske fakultet, Universitetet i Oslo; 2009.
  173. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349(9):859–66.
  174. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research, Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29(16):2171–7.
  175. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48(2):202–5.
  176. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. Eur Urol 2013;66(1):42–54.
  177. Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist 2016;21(6):708–15.
  178. Ghadjar P, Burkhard FC, Gautschi O, Thalmann GN, Studer UE. Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU Int 2011;107(6):894–7.
  179. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165(3):811–4.
  180. Nieuwenhuijzen JA, Bex A, Meinhardt W, Kerst JM, Schornagel JH, H VANT, et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 2005;174(1):80–5.
  181. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001;19(20):4005–13.
  182. Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, et al. Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. J Clin Oncol 2014;32(18):1889–94.
  183. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, et al. Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. J Clin Oncol 2014;32(18):1895–901.
  184. Burger M, Mulders P, Witjes W. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur Urol 2012;61(5):1070–1.
  185. Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2011;29(3):252–8.
  186. Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009;55(1):177–85.
  187. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155(2):495–9; discussion 9–500.
  188. Lehmann J, Franzaring L, Thuroff J, Wellek S, Stockle M. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 2006;97(1):42–7.
  189. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145(3):459–64.
  190. Stockle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, et al. Adjuvant poly­chemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995;153(1):47–52.
  191. Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010;16(17):4461–7.
  192. Vetterlein MW, Seisen T, May M, Nuhn P, Gierth M, Mayr R, et al. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. Eur Urol Focus 2018;4(2):252–9.
  193. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 2015;16(1):76–86.
  194. Kava BR, Abol-Enein H, Baniel J, Carmack A, Coquhoun A, Turner W. Non-urothelial Cancer of the Urinary Bladder. I: Soloway MS, Khoury S, red. Bladder Cancer. 2. utg. Paris: European Association of Urology og ICUS; 2012. s. 409–32. Tilgjengelig fra: http://www.icud.info/PDFs/Bladder%20Cancer%20Second%20Edition%202012.pdf 
  195. Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Löppenberg B, Chun FK, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer 2017;123(22):4346–55.
  196. Khan MS, Thornhill JA, Gaffney E, Loftus B, Butler MR. Keratinising squamous metaplasia of the bladder: natural history and rationalization of management based on review of 54 years experience. Eur Urol 2002;42(5):469–74.
  197. Cutress ML, Stewart GD, Wells-Cole S, Phipps S, Thomas BG, Tolley DA. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int 2012;110(11):1608–17.
  198. Hoffman A, Yossepowitch O, Erlich Y, Holland R, Lifshitz D. Oncologic results of nephron sparing endoscopic approach for upper tract low grade transitional cell carcinoma in comparison to nephroureterectomy – a case control study. BMC Urol 2014;14:97.
  199. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115(6):1224–33.
  200. Wang JK, Tollefson MK, Krambeck AE, Trost LW, Thompson RH. High rate of pathologic upgrading at nephroureterectomy for upper tract urothelial carcinoma. Urology 2012;79(3):615–9.
  201. Rouprët M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 2013;63(6):1059–71.
  202. Walton TJ, Sherwood BT, Parkinson RJ, Obakponovwe O, Thomas SA, Taylor MC, et al. Comparative outcomes following endoscopic ureteral detachment and formal bladder cuff excision in open nephroureterectomy for upper urinary tract transitional cell carcinoma. J Urol 2009;181(2):532–9.
  203. Macejko AM, Pazona JF, Loeb S, Kimm S, Nadler RB. Management of distal ureter in laparoscopic nephroureterectomy--a comprehensive review of techniques. Urology 2008;72(5):974–81.
  204. Capitanio U, Shariat SF, Isbarn H, Weizer A, Remzi M, Roscigno M, et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 2009;56(1):1–9.
  205. Fairey AS, Kassouf W, Estey E, Tanguay S, Rendon R, Bell D, et al. Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. BJU Int 2013;112(6):791–7.
  206. Simone G, Papalia R, Guaglianone S, Ferriero M, Leonardo C, Forastiere E, et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur Urol 2009;56(3):520–6.
  207. Colin P, Ouzzane A, Pignot G, Ravier E, Crouzet S, Ariane MM, et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 2012;110(8):1134–41.
  208. Lughezzani G, Jeldres C, Isbarn H, Shariat SF, Sun M, Pharand D, et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2010;75(1):118–24.
  209. Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011;60(4):776–83.
  210. Matin SF, Sfakianos JP, Espiritu PN, Coleman JA, Spiess PE. Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. J Urol 2015;194(6):1567–74.
  211. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K. Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract. Urology 2007;69(2):265–9.
  212. Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, et al. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol 2009;56(3):512–8.
  213. O’Brien T, Ray E, Singh R, Coker B, Beard R. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011;60(4):703–10.
  214. Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013;31(11):1422–7.
  215. Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014;66(3):529–41.
  216. Seisen T, Krasnow RE, Bellmunt J, Roupret M, Leow JJ, Lipsitz SR, et al. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol 2017;35(8):852–60.
  217. Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol 2014;32(1):31.e17–24.
  218. Giercksky K-E, Grønbech JE, Hammelbo T, Hirshberg H, Lundar T, Mjåland O, et al. Bruk av palliativ kirurgi i behandlingen av kreftpasienter. Oslo: Sintef; 2003. SMM-rapport Nr. 8/2003. Tilgjengelig fra: www.kunnskapssenteret.no/publikasjoner/_attachment/172405?_ts=14855a78a2d 
  219. Arrizabalaga M, Extramiana J, Parra JL, Ramos C, Diaz Gonzalez R, Leiva O. Treatment of massive haematuria with aluminous salts. Br J Urol 1987;60(3):223–6.
  220. Ghahestani SM, Shakhssalim N. Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. Urol J 2009;6(3):149–56.
  221. Liguori G, Amodeo A, Mucelli FP, Patel H, Marco D, Belgrano E, et al. Intractable haematuria: long-term results after selective embolization of the internal iliac arteries. BJU Int 2010;106(4):500–3.
  222. Oliai C, Fisher B, Jani A, Wong M, Poli J, Brady LW, et al. Hyperbaric Oxygen Therapy for Radiation-Induced Cystitis and Proctitis. Int J Radiat Oncol Biol Phys 2012;84(3):733–40.
  223. Aass N, Haugne DF, Rosland JH, HJordhøy M, Dønnem T, Knudsen AK. Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen. 5. utg. Oslo: Helsedirektoratet; 2015. IS-2285. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen 
  224. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010;15(4):382–9.
  225. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013;63(2):309–20.
  226. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol 2005;174(1):14–20.
  227. Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 2003;46(Suppl):S105-S15.
  228. Stenzl A, Cowan NC, De SM, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59(6):1009–18.
  229. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77.
  230. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602–8.
  231. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. J Clin Oncol 2012;30(2):191–9.
  232. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017;376(11):1015–26.
  233. Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391(10122):748–57.
  234. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312–22.
  235. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454–61.
  236. Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 2013;24(6):1466–72.
  237. Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol 2016;195(2):254–63.
  238. Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 2016;27(1):49–61.
  239. Vogelzang NJ. Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma. J Clin Oncol 2013;31(6):670–5.
  240. Duchesne GM, Bolger JJ, Griffiths GO, Trevor Roberts J, Graham JD, Hoskin PJ, et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys 2000;47(2):379–88.
  241. Sengelov L, von der Maase H. Radiotherapy in bladder cancer. Radiother Oncol 1999;52(1):1–14.
  242. Guzzo TJ, Rogers CG, Deng CY, Bivalacqua TJ, Palapattu GS, Bastian PJ, et al. Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease. BJU Int 2008;102(11):1539–43.
  243. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, et al. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 2005;174(6):2186–90.
  244. Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, et al. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 2003;170(5):1868–71.
  245. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol 2003;169(6):2113–7.
  246. Nieuwenhuijzen JA, Horenblas S, Meinhardt W, van Tinteren H, Moonen LM. Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int 2004;94(6):793–7.
  247. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002;167(4):1634–7.
  248. Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 2005;173(4):1108–11.
  249. Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000;164(3 Pt 1):685–9.
  250. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466–5.
  251. Borhan A, Reeder JE, O’Connell MJ, Wright KO, Wheeless LL, di Sant’Agnese PA, et al. Grade progression and regression in recurrent urothelial cancer. J Urol 2003;169(6):2106–9.
  252. Fujii Y, Kawakami S, Koga F, Nemoto T, Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 2003;92(6):559–62.
  253. Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 2006;49(2):303–6.
  254. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001;165(4):1124–8.
  255. Leblanc B, Duclos AJ, Benard F, Cote J, Valiquette L, Paquin JM, et al. Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol 1999;162(6):1946–50.
  256. Oge O, Erdem E, Atsü N, ahin A, Ozen H. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. Eur Urol 2000;37(3):271–4.
  257. Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003;170(2 Pt 1):438–41.
  258. Zieger K, Wolf H, Olsen PR, Hojgaard K. Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression. BJU Int 2000;85(7):824–8.
  259. Cancer i urinblåsa, njurbäcken, urin-ledare och urinrör: nationellt vårdprogram. rev. utg. Lund: Regionala cancercentrum i Samverkan; 2015. Tilgjengelig fra: http://www.cancercentrum.se/globalassets/cancerdiagnoser/urinvagar/urinblase--och-urinrorscancer/vardprogram/natvp_cancer_urinvagar_25aug15.pdf 
  260. Herr HW, Cookson MS, Soloway SM. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 1996;156(4):1286–7.
  261. Hurle R, Losa A, Manzetti A, Lembo A. Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. Urology 1999;53(6):1144–8.
  262. Choe J, Braschi-Amirfarzan M, Tirumani SH, Shinagare AB, Kim KW, Ramaiya NH, et al. Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. Abdom Radiol (NY) 2017;42(11):2710–24.
  263. Aziz NM. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol 2007;46(4):417–32.
  264. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012;30(30):3752–63.
  265. Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 2013;31(30):3807–14.
  266. Majewski W, Tarnawski R. Acute and late toxicity in radical radiotherapy for bladder cancer. Clin Oncol (R Coll Radiol) 2009;21(8):598–609.
  267. Søndergaard J, Holmberg M, Jakobsen AR, Agerbæk M, Muren LP, Høyer M. A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta Oncol 2014;53(10):1321–8.
  268. Mangar SA, Foo K, Norman A, Khoo V, Shahidi M, Dearnaley DP, et al. Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer. Clin Oncol (R Coll Radiol) 2006;18(6):466–73.
  269. Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, et al. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol 2006;81(1):9–17.
  270. Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89–03, 95–06, 97–06, 99–06. J Clin Oncol 2009;27(25):4055–61.
  271. Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007;68(4):1072–80.
  272. Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60(1):62–7; discussion 7–8.
  273. Lagrange JL, Bascoul-Mollevi C, Geoffrois L, Beckendorf V, Ferrero JM, Joly F, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97–015). Int J Radiat Oncol Biol Phys 2011;79(1):172–8.
  274. Herman JM, Smith DC, Montie J, Hayman JA, Sullivan MA, Kent E, et al. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology 2004;64(1):69–73.
  275. Sharks JH, Chandra A, McWilliam L, Varma M. Standards and datasets for reporting cancers: dataset for tumours of the urinary collecting system (renal pelvis, ureter, urinary bladder and urethra). 2. utg. London: The Royal College of Pathologists; 2013. Tilgjengelig fra: https://www.rcpath.org/asset/E2C11FF6-780A-471E-A21A4DC48788D35B/ 
  276. Veileder i biopsibesvarelse av maligne svulster. 3. utg. Oslo: Den norske patologforening; 2016. Tilgjengelig fra: http://legeforeningen.no/Global/Fagmedisinske%20foreninger/Den%20norske%20patologforening/Veileder%20i%20besvarelse%20av%20maligne%20svulster%202016%203%20%20utgave.pdf 
  277. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4–34.
  278. El-Bolkainy MN, Chu EW, Ghoneim MA, Ibrahim AS. Cytologic detection of bladder cancer in a rural Egyptian population infected with schistosomiasis. Acta Cytol 1982;26(3):303–10.
  279. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al., red. Cancer Incidence in Five Continents. Lyon: IARC; 2007. IARC Scientific Publications No. 160.
  280. Kim SP, Frank I, Cheville JC, Thompson RH, Weight CJ, Thapa P, et al. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol 2012;188(2):405–9.
  281. Wasco MJ, Daignault S, Zhang Y, Kunju LP, Kinnaman M, Braun T, et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007;70(1):69–74.
  282. Lee YJ, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma. PloS One 2014;9(9):e107027.
  283. Moch H, Humphrey PA, Ulbright TM, Reuter VE, red. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4. utg. Lyon: IARC; 2016.
  284. Mostofi FK, Davis CJ, Sesterhenn IA. Histological typing of urinary bladder tumours. 2. utg. Berlin og New York: Springer; 1999.
  285. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002;441(2):105–8.
  286. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. Geneva: World Health Orgaization; 1973. International histological classification of tumours No. 10. Tilgjengelig fra: http://apps.who.int/iris/bitstream/10665/41533/1/9241760109_eng.pdf 
  287. Eble JN, Sauter G, Epstein JI, Sesterhenn I, red. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.
  288. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22(12):1435–48.
  289. Gönul, II, Akyürek N, Dursun A, Küpeli B. Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract 2008;204(10):707–17.
  290. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Pauwels RP, Newling DW, ten Kate F. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol 2002;55(12):900–5.
  291. Chen Z, Ding W, Xu K, Tan J, Sun C, Gou Y, et al. The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer. PloS One 2012;7(10):e47199.
  292. Renal pelvis and ureter. I: Amin M, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al., red. AJCC cancer staging manual. 8. utg. Chicago: American Joint Committee on Cancer, Springer 2017. s. 757–65.
  293. Van Der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 2000;164(5):1533–7.
  294. Amin M, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al., red. AJCC cancer staging manual. 8. utg. Chicago: American Joint Committee on Cancer, Springer 2017.
  295. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, et al. Focus on bladder cancer. Cancer Cell 2004;6(2):111–6.
  296. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER, Jöbsis AC, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64(6):1911–4.
  297. Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72(3):354–65.
  298. Eriksson P, Aine M, Veerla S, Liedberg F, Sjödahl G, Höglund M. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. BMC Med Genomics 2015;8:25.
  299. Nasjonal helseplan (2007–2010). Oslo: Helse- og omsorgsdepartemenetet; 2006. Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6. Tilgjengelig fra: http://www.regjeringen.no/upload/HOD/Sykehus/​Nasjonal_helseplan_Sartrykk.pdf 
  300. Nasjonale faglige retningslinjer, veiledere og kvalitetsindikatorer. § 12‑5 I: Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30. Tilgjengelig fra: https://lovdata.no/lov/2011-06-24-30/§12-5 
  301. Nasjonal strategi for kreftområdet 2006–2009. Oslo: Helse- og omsorgsdepartementet; 2006. Tilgjengelig fra: https://www.regjeringen.no/globalassets/upload/hod/sykehus/kreftstrategi-2006-2009.pdf 
  302. Sammen – mot kreft: nasjonal kreftstrategi 2013–2017. Oslo: Helse- og omsrogsdepartementet; 2013. Tilgjengelig fra: https://www.regjeringen.no/contentassets/07cd14ff763444a3997de1570b85fad1/​kreftstrategien_2013.pdf 
  303. Wahlquist R. Handlingsprogram for blærecancer: retningslinjer for utredning, behandling og kontroll. [s.l.]: Norsk Urologisk Cancergruppe; 2005.
  304. Babjuk M, Böhle A, Burger M, Compérat E, Kaasinen E, Palou J, et al. Guidelines on non-muscle invasive bladder cancer (TaT1 and CIS). rev. utg. Arnhem: European Association of Urology; 2011. Tilgjengelig fra: https://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-2015-v1.pdf 
  305. Babjuk M, Burger M, Zigeuner R, Shariat S, Van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2011;64(4):639–53.
  306. Heller MT, Tublin ME. In search of a consensus: evaluation of the patient with hematuria in an era of cost containment. AJR Am J Roentgenol 2014;202(6):1179–86.
  307. Maurer T, Horn T, Heck M, Gschwend JE, Eiber M, Beer AJ. Current Staging Procedures in Urinary Bladder Cancer. Diagnostics (Basel) 2013;3(3):315–24.
  308. O’Connor OJ, Fitzgerald E, Maher MM. Imaging of hematuria. AJR Am J Roentgenol 2010;195(4):W263–7.
  309. Moloney F, Murphy KP, Twomey M, O’Connor OJ, Maher MM. Haematuria: an imaging guide. Adv Urol 2014;2014: 414125.
  310. Helenius M, Dahlman P, Magnusson M, Lönnemark M, Magnusson A. Contrast enhancement in bladder tumors examined with CT urography using traditional scan phases. Acta Radiol 2014;55(9):1129–36.
  311. Takeuchi M, Konrad AJ, Kawashima A, Boorjian SA, Takahashi N. CT Urography for Diagnosis of Upper Urinary Tract Urothelial Carcinoma: Are Both Nephrographic and Excretory Phases Necessary? AJR Am J Roentgenol 2015;205(3):W320–7.
  312. Bouchelouche K, Turkbey B, Choyke PL. PET/CT and MRI in Bladder Cancer. J Cancer Sci Ther 2012;S14(1):pii: 7692.
  313. Foroudi F, Pham D, Bressel M, Wong J, Rolfo A, Roxby P, et al. Bladder cancer radiotherapy margins: a comparison of daily alignment using skin, bone or soft tissue. Clin Oncol (R Coll Radiol) 2012;24(10):673–81.